<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00308308</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-009</org_study_id>
    <nct_id>NCT00308308</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of Inhaled Insulin in Type 1 Diabetes</brief_title>
  <official_title>A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the Mean Change From Baseline to Week 52 in HbA1c</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weight to Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Change from baseline in weight at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose to Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Change from baseline in fasting plasma glucose at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Number of subjects achieving week 52 HbA1c levels less than or equal to 7.0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Total Hypoglycemia</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement &lt;= 63 mg/dL, regardless of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Severe Hypoglycemia</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Severe hypoglycemia occurs when all 3 of the following occur simultaneously:
Subject requires the assistance of another person;
Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness);
Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR,
Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hypoglycemia Event Rate</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Number of Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Hypoglycemia Event Rate</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">589</enrollment>
  <condition>Diabetes, Type I</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Technosphere Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapid-acting analogue insulin plus basal insulin glargine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere Insulin</intervention_name>
    <description>Inhalation, 15U/30U</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator</intervention_name>
    <description>sc injectable insulin</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of type 1 diabetes for at least 1 year

          -  Nonsmokers for prior 6 months

          -  BMI less than or equal to 35kg/m2

          -  HbA1c &gt; or = 7% and &lt; or = 11%

          -  Serum creatinine &lt; or = 1.8 mg/dL in female subjects and &lt; or = 2.0 mg/dL in male
             subjects

          -  FEV1 &gt; or = 70% of predicted, DLco &gt; or = 70% , TLC &gt; or = 80% predicted

          -  Maintenance of a treatment regimen of insulin less than or equal to 1.4 iu/kg/day

          -  Urine cotinine &lt; or = 100 ng/mL

        Exclusion Criteria:

          -  History of chronic obstructive pulmonary disease, asthma, any other clinically
             significant pulmonary disease confirmed by documented history, pulmonary function
             testing or radiologic findings

          -  Evidence of severe complications of diabetes

          -  Aminotransferase and/or alanine aminotransferase &gt; than 3 times the upper limit of
             normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Coastal Clinical Research Inc</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research (Phoenix)</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research Network</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medical Center</name>
      <address>
        <city>Foothill Ranch</city>
        <state>California</state>
        <zip>92610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes/Lipid Management and Research Center</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bay Clinical Research</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Biomedical Research Inc</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Associates LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laureate Clinical Research Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Pharmaceutical Research Center</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Atlanta Endocrinology &amp; Diabetes PC</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Research Solutions, Inc.</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H Stoger Jr Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintell Inc</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research of Louisiana</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oschner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James A Dicke MDPA</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Medicine</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KMED Research</name>
      <address>
        <city>St Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc (Minneapolis)</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Urologic Clinical Trials University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedEx Healthcare Research Inc(009)</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amin Radparvar's Private Practice</name>
      <address>
        <city>St Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic Research Division</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton Diabetes Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico HCS</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Diabetes and Endocrine Associates</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Physicians Group Endocrine Division</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Research - Physician's East PA</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Partners - Center of Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Diabetes &amp; Endocrinology Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Clinical Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance CRU Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Research Institute</name>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <zip>19020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Associates Inc</name>
      <address>
        <city>Williamston</city>
        <state>South Carolina</state>
        <zip>29697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AM Diabetes and Endocrinology Center</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Endocrine Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Israel Hartman MD</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes &amp; Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Dallas-North</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spuhler Medical Associates</name>
      <address>
        <city>Friendswood</city>
        <state>Texas</state>
        <zip>77546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Assurance Research Center (900)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Glandular Disease Research Assoc PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAM Clinical Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Bali MD PA</name>
      <address>
        <city>Seguin</city>
        <state>Texas</state>
        <zip>78155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Salt Lake City</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salt Lake Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larry D Stonesifer MD Inc PS</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Research</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberty Research Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Interzonal de Agudos Pedro Fiorito</name>
      <address>
        <city>Avellaneda</city>
        <state>Buenos Aires</state>
        <zip>B1870ARG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Endocrinologic Tiempo</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1117ABH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Durand /Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405CWB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gral De Agudos Dr. Teodoro Alvarez</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1406FWY</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cons Asoc de Endocrinologia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Dra De Salvo</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIMeL</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Estabual de Maringa</name>
      <address>
        <city>Maringa Parana</city>
        <zip>87020-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleo de Medicina Integrada</name>
      <address>
        <city>Mogi das Cruzes</city>
        <zip>08780-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Estadual De Diabetes e Endocrinologia Luis Capriglione</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20211-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ccbr Brasil Centro de Analises e Pesquisas Clinicas Ltda</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Guilherme Alvaro</name>
      <address>
        <city>Santos</city>
        <zip>11045-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPClin-Centro de Pesquisas Clinicas</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Diabetes/UNIFESP-EPM</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04020-041</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenau Servicos Medicos S/C Ltda</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05302-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica e Medicina Avancada</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05437-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifestyle Metabolism Center</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifestyle Metabolism Center</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J 8L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifestyle Metabolism Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4R 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Professional Research</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Salvador</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Jose</name>
      <address>
        <city>Santiago</city>
        <zip>1196</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Pontificia Universidad (009)Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Padre Alberto Hurtado</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Borja ArriaranUniversidad de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Informacion de Tramiento y Educacion en Salud</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Mexicano de Investigacion</name>
      <address>
        <city>Mexico City</city>
        <state>Durango</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Engracia-CIMA</name>
      <address>
        <city>Garza Garcia</city>
        <zip>66260</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios en Diabetes</name>
      <address>
        <city>Mexico City</city>
        <zip>01120</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Mexico Servicio EndocrinologiaJefe Del Servicio</name>
      <address>
        <city>Mexico City</city>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital OCA-MIRC (009)</name>
      <address>
        <city>Monterrey</city>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczny Osrodek Internistyczno - Diabetologiczny</name>
      <address>
        <city>Bialystok</city>
        <state>POL</state>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra I Klinika Chorob Metabolicznych Collegium Medicum Uniwersytety Jagiellonskiego</name>
      <address>
        <city>Krakow</city>
        <state>POL</state>
        <zip>31 501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia (009) Matki Polki</name>
      <address>
        <city>Lodz</city>
        <state>POL</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kolejowy im Dr w Roeflera(009) Oddzial Gastorenterologii</name>
      <address>
        <city>Pruszkow</city>
        <state>POL</state>
        <zip>05 800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Chorob Wewnetrznych (009 Endokrynologii I Diabetologii Szpitala Wojewodzkiego</name>
      <address>
        <city>Bialystok</city>
        <zip>15-950</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Kliniczny Diabetologii (009) Kliniczny nr 1 im Norberta Barlickiego Uniwersytety Meycznego</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Diabetologiczna Poradnia Specjalistyczna</name>
      <address>
        <city>Warszawa</city>
        <zip>01-911</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHI Kemerovo Regional Clinical Hospital</name>
      <address>
        <city>Kemerovo</city>
        <state>RUS</state>
        <zip>650061</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NI Principal Military Clinical Hospital n a academician N.N. Burdenko of the Ministry of Defense</name>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEI HPE Moscow State University of Medicine and Dentistry of FAHSD City Clinical Hospital #70</name>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>111399</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Clinical Hospital # 13</name>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SEI HPE Moscow Medical Academy IM Sechenov of Roszdrav Clinic of Endocrinology</name>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Internal Affairs of Moscow- Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>125299</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAAMS Endocrinology and Diabetology Department</name>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIH of Moscow City Clinical Hopsital #81Endocrinology and Diabetology</name>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>127644</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Petersburg NHI City Polytclinic #77 City Diabetological Center #4</name>
      <address>
        <city>St Petersburg</city>
        <state>RUS</state>
        <zip>193012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Medical Sanitary Unit #122</name>
      <address>
        <city>St Petersburg</city>
        <state>RUS</state>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavlov State Medical Univ of St Petersburg</name>
      <address>
        <city>St Petersburg</city>
        <state>RUS</state>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Petersburg NHI Municipal Multi-Speciality Hospital # 2</name>
      <address>
        <city>St. Petersburg</city>
        <state>RUS</state>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHI Clinical Hospital for Emergency Care na NV Soloviev</name>
      <address>
        <city>Yaroslavl</city>
        <state>RUS</state>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCHI Medical Sanitary Unit of Novo-Yaroslavsky Oil Refining Plant</name>
      <address>
        <city>Yaroslavl</city>
        <state>RUS</state>
        <zip>150023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHI Yaroslavl Regional Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <state>RUS</state>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 61</name>
      <address>
        <city>Moscow</city>
        <zip>119 048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Scientific Center of Restoration Medicine &amp; Balneology</name>
      <address>
        <city>Moscow</city>
        <zip>121069</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Nuestra Senora de Valme</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena (policlinico) 2ª planta Servicio de Endocrinologia y Nutricion</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birchwood Surgery</name>
      <address>
        <city>Letchworth</city>
        <state>Herts</state>
        <zip>SG6 4UB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <state>Herts</state>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandwell General Hospital</name>
      <address>
        <city>Lyndon</city>
        <state>West Bromwich</state>
        <zip>B71 4HJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaxley Group Practice</name>
      <address>
        <city>Peterborough</city>
        <zip>PE7 3JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2006</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>October 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 16, 2014</results_first_posted>
  <disposition_first_submitted>June 9, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 1, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2009</disposition_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient enrolled Feb, 2006 Multi-national trial conducted in US, Canada, Mexico, Brazil, Argentina, Chile, Spain, UK, Poland, Russia</recruitment_details>
      <pre_assignment_details>3 week Screening Period prior to randomization – 1420 Screened / 598 Eligible of which 589 were randomized - 822 screen failures 24 Subjects randomized but never dosed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TI + Insulin Glargine</title>
          <description>TI + Insulin glargine</description>
        </group>
        <group group_id="P2">
          <title>Insulin Aspart + Insulin Glargine</title>
          <description>Comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="288"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Various</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not dosed</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population (589 were randomized - 24 Subjects randomized but never dosed)</population>
      <group_list>
        <group group_id="B1">
          <title>TI + Insulin Glargine</title>
          <description>TI + Insulin glargine</description>
        </group>
        <group group_id="B2">
          <title>Insulin Aspart + Insulin Glargine</title>
          <description>Comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="293"/>
            <count group_id="B2" value="272"/>
            <count group_id="B3" value="565"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.9" spread="13.06"/>
                    <measurement group_id="B2" value="38.1" spread="13.18"/>
                    <measurement group_id="B3" value="38" spread="13.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>Glycosylated Hemoglobin</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="0.95"/>
                    <measurement group_id="B2" value="8.5" spread="0.97"/>
                    <measurement group_id="B3" value="8.5" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Weight in kilograms</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.7" spread="15.64"/>
                    <measurement group_id="B2" value="76.8" spread="14.95"/>
                    <measurement group_id="B3" value="76.7" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Compare the Mean Change From Baseline to Week 52 in HbA1c</title>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Intention to treat (ITT) with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>TI + Insulin Glargine</title>
            <description>TI + Insulin glargine</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Compare the Mean Change From Baseline to Week 52 in HbA1c</title>
          <population>Intention to treat (ITT) with Last Observation Carried Forward (LOCF)</population>
          <units>Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.058"/>
                    <measurement group_id="O2" value="-0.37" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size was set to meet regulatory requirement of 250 subjects per arm with 52‑week data, resulting in &gt; 90% power for a non‑inferiority test of the difference in 12‑month change of HbA1c scores between treatment groups with non‑inferiority margin of 0.4%, standard deviation of 1.2 and 1‑sided alpha of 0.025. Allowing for a 15% dropout rate, 589 subjects were randomized.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.082</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weight to Week 52</title>
        <description>Change from baseline in weight at Week 52</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>participants in ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>TI + Insulin Glargine</title>
            <description>TI + Insulin glargine</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight to Week 52</title>
          <description>Change from baseline in weight at Week 52</description>
          <population>participants in ITT population with available data</population>
          <units>kilogram</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.32"/>
                    <measurement group_id="O2" value="1.4" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with terms of pooled site and treatment as fixed effects and baseline weight as covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose to Week 52</title>
        <description>Change from baseline in fasting plasma glucose at Week 52</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>participants in ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>TI + Insulin Glargine</title>
            <description>TI + Insulin glargine</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose to Week 52</title>
          <description>Change from baseline in fasting plasma glucose at Week 52</description>
          <population>participants in ITT population with available data</population>
          <units>mg/dl</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.5" spread="5.61"/>
                    <measurement group_id="O2" value="-25.7" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0052</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-20.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.4</ci_lower_limit>
            <ci_upper_limit>-6.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%</title>
        <description>Number of subjects achieving week 52 HbA1c levels less than or equal to 7.0%</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>participants in ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>TI + Insulin Glargine</title>
            <description>TI + Insulin glargine</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%</title>
          <description>Number of subjects achieving week 52 HbA1c levels less than or equal to 7.0%</description>
          <population>participants in ITT population with available data</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>logistic regression analysis with the terms of treatment and baseline HbA1c in the model</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8311</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.941</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.536</ci_lower_limit>
            <ci_upper_limit>1.652</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Total Hypoglycemia</title>
        <description>Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement &lt;= 63 mg/dL, regardless of symptoms.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>TI + Insulin Glargine</title>
            <description>TI + Insulin glargine</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Total Hypoglycemia</title>
          <description>Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement &lt;= 63 mg/dL, regardless of symptoms.</description>
          <population>Safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.67"/>
                    <measurement group_id="O2" value="92.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0124</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.488</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.278</ci_lower_limit>
            <ci_upper_limit>0.856</ci_upper_limit>
            <estimate_desc>Model: Treatment + Site</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Severe Hypoglycemia</title>
        <description>Severe hypoglycemia occurs when all 3 of the following occur simultaneously:
Subject requires the assistance of another person;
Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness);
Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR,
Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>TI + Insulin Glargine</title>
            <description>TI + Insulin glargine</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Severe Hypoglycemia</title>
          <description>Severe hypoglycemia occurs when all 3 of the following occur simultaneously:
Subject requires the assistance of another person;
Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness);
Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR,
Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.</description>
          <population>Safety Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.08"/>
                    <measurement group_id="O2" value="36.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2786</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.825</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.582</ci_lower_limit>
            <ci_upper_limit>1.169</ci_upper_limit>
            <estimate_desc>Model: Treatment + Site</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hypoglycemia Event Rate</title>
        <description>Number of Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>TI + Insulin Glargine</title>
            <description>TI + Insulin glargine</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hypoglycemia Event Rate</title>
          <description>Number of Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
          <population>Safety Population</population>
          <units>Number of events/subject-month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81"/>
                    <measurement group_id="O2" value="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1193</p_value>
            <method>Generalized Estimation Equation</method>
            <method_desc>Based on Poisson distribution
Model: Treatment + Time Period</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Hypoglycemia Event Rate</title>
        <description>Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>TI + Insulin Glargine</title>
            <description>TI + Insulin glargine</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Hypoglycemia Event Rate</title>
          <description>Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
          <population>Safety Population</population>
          <units>Number of events/subject-month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08"/>
                    <measurement group_id="O2" value="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2131</p_value>
            <method>Generalized Estimating Equation</method>
            <method_desc>Based on Poisson distribution
Model: Treatment + Time Period</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose to 30 days after last dose</time_frame>
      <desc>Safety population is the at risk population</desc>
      <group_list>
        <group group_id="E1">
          <title>TI + Insulin Glargine</title>
          <description>TI + Insulin glargine</description>
        </group>
        <group group_id="E2">
          <title>Insulin Aspart + Insulin Glargine</title>
          <description>Comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hepatocellular damage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Metabolic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="265" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="257" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="252" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>MannKind Corporation</organization>
      <phone>201-983-5000</phone>
      <email>aboss@mannkindcorp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

